Telaprevir in Genotype 3 HCV (TIG3)
Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin
Sponsor: Barts & The London NHS Trust
Listed as NCT02087111, this PHASE4 trial focuses on Hepatitis C and remains completed. Sponsored by Barts & The London NHS Trust, it has been updated 6 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
-
Jan 2021 — Feb 2023 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Barts & The London NHS Trust
- Bradford Teaching Hospitals NHS Foundation Trust
- Janssen-Cilag Ltd.
- Nottingham University Hospitals NHS Trust
- Queen Mary University of London
- St George's Healthcare NHS Trust
For direct contact, visit the study record on ClinicalTrials.gov .